Myers KA, et al. - This research was initiated in order to contemplate the long-term safety and efficacy of stiripentol as an antiepileptic medication in patients with Dravet syndrome and ongoing seizures. An improvement was achieved in the long-term seizure frequency in approximately 50% of patients with Dravet syndrome due to stiripentol, when used as a part of unrestricted polytherapy. Data illustrated the safety of its long-term use. A significant decrease was found in the episodes of status epilepticus after stiripentol initiation in more than 40% of the patients.